Pimodivir plus standard of care for non-hospitalized high-risk influenza A

Phase 3, randomised, double-blind trial in Influenza A infection comparing Pimodivir + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to resolution of influenza-related symptoms. Started Sep 2018; status: completed.